56 related articles for article (PubMed ID: 106277)
1. Prostatic carcinoma.
Klein LA
N Engl J Med; 1979 Apr; 300(15):824-33. PubMed ID: 106277
[No Abstract] [Full Text] [Related]
2. Effect of androgen blockade on HER-2 and matrix metalloproteinase-2 expression on bone marrow micrometastasis and stromal cells in men with prostate cancer.
Murray NP; Reyes E; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R
ScientificWorldJournal; 2013; 2013():281291. PubMed ID: 23766685
[TBL] [Abstract][Full Text] [Related]
3. Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol.
Murray NP; Badinez LV; Dueñas RR; Orellana N; Tapia P
Indian J Urol; 2011 Apr; 27(2):200-7. PubMed ID: 21814310
[TBL] [Abstract][Full Text] [Related]
4. The periodic health examination.
Bartlett LC
Can Med Assoc J; 1981 Feb; 124(4):367-70. PubMed ID: 20313538
[No Abstract] [Full Text] [Related]
5. Urology-epitomes of progress: immediate versus delayed endocrine therapy for prostatic carcinoma.
Barnes R; Hadley H; Bergman RT
West J Med; 1981 Apr; 134(4):345-6. PubMed ID: 18748850
[No Abstract] [Full Text] [Related]
6. Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
Yamamoto N; Suyama H; Yamamoto N
Transl Oncol; 2008 Jul; 1(2):65-72. PubMed ID: 18633461
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer.
Carles Galcerán J; Bastus Piulats R; Martín-Broto J; Maroto Rey P; Nogué Aligué M; Domenech Santasusana M; Arcusa Lanza A; Bellmunt Molins J; Colin C; Girard A
Clin Transl Oncol; 2005 Mar; 7(2):66-73. PubMed ID: 15899211
[TBL] [Abstract][Full Text] [Related]
8. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.
West AF; O'Donnell M; Charlton RG; Neal DE; Leung HY
Br J Cancer; 2001 Aug; 85(4):576-83. PubMed ID: 11506499
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor gene and hormonal therapy failure of prostate cancer.
Koivisto P; Kolmer M; Visakorpi T; Kallioniemi OP
Am J Pathol; 1998 Jan; 152(1):1-9. PubMed ID: 9422516
[TBL] [Abstract][Full Text] [Related]
10. Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.
Fuse H; Muraishi Y; Fujishiro Y; Katayama T
Int Urol Nephrol; 1996; 28(1):79-85. PubMed ID: 8738624
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate.
Seidmon EJ; Trump DL; Kreis W; Hall SW; Kurman MR; Ouyang SP; Wu J; Kremer AB
Ann Surg Oncol; 1995 Nov; 2(6):550-6. PubMed ID: 8591087
[TBL] [Abstract][Full Text] [Related]
12. Weekly chemotherapy in advanced prostatic cancer.
Francini G; Petrioli R; Manganelli A; Cintorino M; Marsili S; Aquino A; Mondillo S
Br J Cancer; 1993 Jun; 67(6):1430-6. PubMed ID: 8512828
[TBL] [Abstract][Full Text] [Related]
13. Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.
Canada A; Herman L; Kidd K; Robertson C; Trump D
Cancer Chemother Pharmacol; 1993; 32(1):73-7. PubMed ID: 8462127
[TBL] [Abstract][Full Text] [Related]
14. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker GL; Faulds D
Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
[TBL] [Abstract][Full Text] [Related]
16. Early (stage A) prostatic cancer. VI. A critical look at the follow-up.
Battaglia S; Barbolini G; Botticelli AR; Berri G; Nigrisoli E
Virchows Arch A Pathol Anat Histol; 1982; 395(3):279-88. PubMed ID: 6180549
[TBL] [Abstract][Full Text] [Related]
17. Ultrasonography of the prostate: a preliminary report from Nigeria.
Iko BO; Monu JU; Mangete ED; Nduka NR
Int Urol Nephrol; 1987; 19(3):279-85. PubMed ID: 2444547
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors in malignant diseases of aging.
Johannessen DC; Lønning PE
Drugs Aging; 1992; 2(6):530-45. PubMed ID: 1493356
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer.
Singh D; Doroshow JH; Leong L; Margolin K; Akman S; Raschko J; Somlo G; Morgan R; Harrison J; Cho J
J Cancer Res Clin Oncol; 1992; 119(2):117-20. PubMed ID: 1429827
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.
Elomaa I; Kylmälä T; Tammela T; Viitanen J; Ottelin J; Ruutu M; Jauhiainen K; Ala-Opas M; Roos L; Seppänen J
Int Urol Nephrol; 1992; 24(2):159-66. PubMed ID: 1385586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
